New York, NYCIK 10092584 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
141 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Nuvalent Inc | 17.25M | $1.74B | 25.4% | −742.6K | Reduced |
| 2 | Cogent Biosciences Inc | 9.04M | $321.24M | 4.7% | −9.2K | Reduced |
| 3 | Praxis Precision Medicines I | 903.4K | $266.25M | 3.9% | +62.5K | Added |
| 4 | Centene Corp Del |
| 6.45M |
| $265.34M |
| 3.9% |
| −2.60M |
| Reduced |
| 5 | Viatris Inc | 20.21M | $251.57M | 3.7% | −3.89M | Reduced |
| 6 | Revolution Medicines Inc | 2.89M | $230.56M | 3.4% | −755.7K | Reduced |
| 7 | United Therapeutics Corp Del | 426.0K | $207.57M | 3.0% | 0 | Held |
| 8 | Vera Therapeutics Inc | 4.06M | $205.58M | 3.0% | +418.5K | Added |
| 9 | Celcuity Inc | 1.71M | $170.95M | 2.5% | +980.5K | Added |
| 10 | Neurocrine Biosciences Inc | 1.18M | $167.98M | 2.5% | 0 | Held |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio